How many clinical trials are studying QL1706 (bispecific antibody targeting PD-1 and CLTA-4)?

3 recruiting trials in our tracked data involve QL1706 (bispecific antibody targeting PD-1 and CLTA-4).

QL1706 (bispecific antibody targeting PD-1 and CLTA-4): clinical trials recruiting now

Q: What conditions is QL1706 (bispecific antibody targeting PD-1 and CLTA-4) being studied for?

In our tracked recruiting trials, QL1706 (bispecific antibody targeting PD-1 and CLTA-4) is being studied in trials for Lung cancer, Breast cancer, Chemoradiotherapy.

Recruiting trials

Conditions studied

US states with sites

Countries

Phase breakdown

Phase 1 1 Phase 2 2

Conditions being studied

Condition	Trials
Lung cancer	2
Breast cancer	1
Chemoradiotherapy	1
Consolidation Immunotherapy	1
Hypertension	1
Induction Therapy	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Limited-stage Small Cell Lung Cancer (LS-SCLC)	1
TNBC, Triple Negative Breast Cancer	1

Recruiting trials involving QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
NCT07091305 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC
NCT07178171 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT07070700 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve QL1706 (bispecific antibody targeting PD-1 and CLTA-4)?

3 recruiting trials across 9 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.